Stock Research Monitor: HEB, HTBX, and PBYI
LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration. On Friday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 1.46%; the Dow Jones Industrial Average edged 0.30% lower; and the S&P 500 was down 0.66%. US markets made broad based losses with all sectors finishing the day in red. Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Amicus Therapeutics Inc. (NASDAQ: FOLD), Hemispherx Biopharma Inc. (NYSE AMER: HEB), Heat Biologics Inc. (NASDAQ: HTBX), and Puma Biotechnology Inc. (NASDAQ: PBYI). All you have to do is sign up today for this free limited time offer by clicking the link below.
Cranbury, New Jersey headquartered Amicus Therapeutics Inc.'s stock finished Friday's session 2.04% lower at $14.89. A total volume of 2.21 million shares was traded. The Company's shares have advanced 12.63% in the last twelve months. The stock is trading above its 200-day moving average by 0.78%. Furthermore, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have a Relative Strength Index (RSI) of 34.83. Get the full research report on FOLD for free by clicking below at:
Shares in Orlando, Florida headquartered Hemispherx Biopharma Inc. ended at $0.31, up 5.14% from the last trading session. The stock recorded a trading volume of 254,469 shares. The stock is trading below its 50-day moving average by 1.29%. Moreover, shares of Hemispherx Biopharma, which engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the US, have an RSI of 50.93. Gain free access to the research report on HEB at:
Durham, North Carolina headquartered Heat Biologics Inc.'s stock ended last Friday's session 3.77% lower at $2.04 with a total trading volume of 196,058 shares. The Company's shares have advanced 78.95% over the previous three months. The stock is trading below its 50-day moving average by 8.86%. Additionally, shares of Heat Biologics, which focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the US, have an RSI of 39.87. Register for your free report coverage on HTBX at:
On Friday, shares in Los Angeles, California headquartered Puma Biotechnology Inc. recorded a trading volume of 562,621 shares. The stock finished the day 2.95% lower at $49.30. The stock is trading below its 50-day moving average by 7.88%. Furthermore, shares of Puma Biotechnology, which focuses on the development and commercialization of products to enhance cancer care in the US, have an RSI of 37.03. Get the free research report on PBYI at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities